FR2988000A1 - Composition pharmaceutique active dans la therapie des affections virales humaines et animales - Google Patents

Composition pharmaceutique active dans la therapie des affections virales humaines et animales Download PDF

Info

Publication number
FR2988000A1
FR2988000A1 FR1200803A FR1200803A FR2988000A1 FR 2988000 A1 FR2988000 A1 FR 2988000A1 FR 1200803 A FR1200803 A FR 1200803A FR 1200803 A FR1200803 A FR 1200803A FR 2988000 A1 FR2988000 A1 FR 2988000A1
Authority
FR
France
Prior art keywords
stigmasterol
sitosterol
methyl
isothiocyanate
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR1200803A
Other languages
English (en)
Inventor
Thomas Wandji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR1200803A priority Critical patent/FR2988000A1/fr
Publication of FR2988000A1 publication Critical patent/FR2988000A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'association de quatre molécules chimiques qui donnent naissance à un médicament virucide dans le traitement thérapeutique des viroses humaines et animales.

Description

BREVET D'INVENTION D'UN MEDICAMENT ANTIVIRAL PAR LE DOCTEUR WANDJI THOMAS 11, allée louis ARAGON, 93160 Noisy- le- Grand(France) TITRE : COMPOSITION PHARMACEUTIQUE ACTIVE DANS LA THERAPIE 5 DES AFFECTIONS VIRALES HUMAINES ET ANIMALES. La présente invention d'un médicament virucide résulte de l'association de quatre molécules chimiques suivantes connues : 1) METHOXY-4 PHENIL1-2METHYL-2ISOTHIOCYANATE DE PROPYL (VIRUCIDE) 10 2) NN' DIBENZYLTHIOUREE sous forme de solution hydro alcoolique (anti oxydant) 3) fi SITOSTEROL 4) STIGMASTEROL L'association de ces produits donne naissance à ce médicament virucide dans le traitement 15 thérapeutique des viroses animales et humaines. a)Viroses Humaines : VIH/SIDA ;ROUGEOLE ; GRIPPE ;VARICELLE ;ZONA ;PSORIASIS ;PAPILLOMA VIRUS DU COL DE L'UTERUS ;INFECTIONS OPPORTUNISTES CHEZ I FS PATIENTS IMMUNO DEPRIMES;SARCOME DE KAPOSI DE LA PEAU ET MUQUEUSE ;GASTRO20 ENTERITES A ROTAVIRUS. b) Viroses animales: FIEVRE APHTEUSE; MALADIE NODULAIRE CUTANEE ; CLAVELEE ; PAPILLOMA ; VIRUS DES MUQUEUSES CANINES

Claims (4)

  1. REVENDICATIONS: I).L'association des quatre molécules chimiques ci-dessus constitue un médicament anti viral I) METHOXY-4 PHENIL1-2METHYL-2ISOTHIOCYANATE DE PROPYL (VIRUCIDE)
  2. 2) NN' DIBENZYLTHIOUREE sous forme de solution hydro alcoolique (anti oxydant)
  3. 3) (3 SITOSTEROL
  4. 4) STIGMASTEROL II) Ce médicament selon la revendication I traverse la membrane cellulaire à une dose déterminée (microgrammes), entre dans la cellule, tue les virus sans toutefois détruire la cellule. III) Ce médicament selon la revendication I et II caractérisé en ce qu'il est présenté sous forme pharmaceutique sirop, lotions ou pommades tue les virus humains et animaux.
FR1200803A 2012-03-16 2012-03-16 Composition pharmaceutique active dans la therapie des affections virales humaines et animales Withdrawn FR2988000A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1200803A FR2988000A1 (fr) 2012-03-16 2012-03-16 Composition pharmaceutique active dans la therapie des affections virales humaines et animales

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1200803A FR2988000A1 (fr) 2012-03-16 2012-03-16 Composition pharmaceutique active dans la therapie des affections virales humaines et animales

Publications (1)

Publication Number Publication Date
FR2988000A1 true FR2988000A1 (fr) 2013-09-20

Family

ID=47553102

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1200803A Withdrawn FR2988000A1 (fr) 2012-03-16 2012-03-16 Composition pharmaceutique active dans la therapie des affections virales humaines et animales

Country Status (1)

Country Link
FR (1) FR2988000A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2966060A4 (fr) * 2013-03-05 2016-08-03 Asahi Kasei Chemicals Corp Procédé de production d'isothiocyanate, composition pour le transport et le stockage de thiocarbamate n-substitué o-substitué, et composition d'isothiocyanate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693106A1 (fr) * 1992-10-02 1994-01-07 Wandji Thomas Association de trois principes actifs extraits du pentadiplandra brazzeana.
WO2003084523A1 (fr) * 2002-04-05 2003-10-16 Thomas Wandji Utilisation du compose nn' dibenzylthiouree comme medicament
US20070093483A1 (en) * 2003-04-25 2007-04-26 Astrazeneca Ab Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo)
EP2177521A1 (fr) * 2008-10-14 2010-04-21 Almirall, S.A. Nouveaux dérivés de 2-amidothiadiazole

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693106A1 (fr) * 1992-10-02 1994-01-07 Wandji Thomas Association de trois principes actifs extraits du pentadiplandra brazzeana.
WO2003084523A1 (fr) * 2002-04-05 2003-10-16 Thomas Wandji Utilisation du compose nn' dibenzylthiouree comme medicament
US20070093483A1 (en) * 2003-04-25 2007-04-26 Astrazeneca Ab Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo)
EP2177521A1 (fr) * 2008-10-14 2010-04-21 Almirall, S.A. Nouveaux dérivés de 2-amidothiadiazole

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EL-MIGIRAB S ET AL: "Isothiocyanates, thiourees et thiocarbamates isoles de Pentadiplandra brazzeana", PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 16, no. 11, 1 January 1977 (1977-01-01), pages 1719 - 1721, XP028087405, ISSN: 0031-9422, [retrieved on 19770101], DOI: 10.1016/0031-9422(71)85078-1 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2966060A4 (fr) * 2013-03-05 2016-08-03 Asahi Kasei Chemicals Corp Procédé de production d'isothiocyanate, composition pour le transport et le stockage de thiocarbamate n-substitué o-substitué, et composition d'isothiocyanate
EP3214071A1 (fr) * 2013-03-05 2017-09-06 Asahi Kasei Chemicals Corporation Composition à base d'isothiocyanate
US10308601B2 (en) 2013-03-05 2019-06-04 Asahi Kasei Chemicals Corporation Isothiocyanate production method, composition for transporting and storing N-substituted O-substituted thiocarbamate, and isothiocyanate composition
US11046645B2 (en) 2013-03-05 2021-06-29 Asahi Kasei Chemicals Corporation Isothiocyanate production method, composition for transporting and storing N-substituted O-substituted thiocarbamate, and isothiocyanate composition

Similar Documents

Publication Publication Date Title
US20120214775A1 (en) Pharmaceutical Salts of 3-O-(3&#39;,3&#39;-Dimethylsuccinyl) Betulinic Acid
US20090191288A1 (en) Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
MX2012007410A (es) Compuestos antivirales novedosos.
US9662360B2 (en) Treatment of herpes, pseudomonas, staph, and hepatitis
FR2988000A1 (fr) Composition pharmaceutique active dans la therapie des affections virales humaines et animales
JP2006504704A (ja) モノアシル化ベツリンおよびジヒドロベツリン誘導体、その製造および使用
Martin Tissue regeneration without scarring achieved by enhancing the alternative cellular energy (ACE) pathway
CN102416041A (zh) 一种抗菌消炎中药组合物及制备方法
KR100906086B1 (ko) 활성 물질로서 도코사헥사엔산을 포함하는 지방이상증 치료를 위한 약제학적 조성물
US20060287364A1 (en) Methods of prevention of infection with HIV/AIDS, venereal disease and influenza
RU2418597C1 (ru) Способ лечения хронического тонзиллита
Viebahn-Haensler Milestones of medical ozone
Bolsunova Ol’ha et al. Izatizon, as an izatin-thiosemicarbazone derivative, has antiviral, anti-tumor actions and no side effects
DE3780157T2 (de) Verwendung von 4-butyl-1,2-diphenyl-pyrazolidin-3,5-dion als antivirales arzneimittel gegen aids.
TW200520747A (en) Medicine composition and medicine for external use containing Houttuynia cordata antiviral ingredient
RU2810444C1 (ru) Способ лечения вульгарных и подошвенных бородавок
KR20140014450A (ko) 테트라케라 스캔덴스 에탄올 추출물을 유효성분으로 포함하는 항바이러스 조성물 및 이의 용도
Waghchaure et al. A REVIEW ON: COVID-19, THE STEP TOWARDS PREVENTION, TREATMENT
CN113940929A (zh) 维拉帕米在制备促使骨代谢进入低转换以防治骨质疏松的产品中的应用
CN117243946A (zh) 瑞香素及包含其的组合物在制备治疗心肌炎药物中的应用
Nuritdinova et al. MODERN MEANS OF PREVENTION AND TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS IN CHILDREN
WO2004108125A1 (fr) Agent d&#39;inactivation de coronavirus
Moravvej et al. Therapeutic Potentiality of Coenzyme Q10 for COVID-19
CA3109802A1 (fr) Produit chimique pour le traitement, la prevention et le controle des maladies virales, des maladies bacteriennes, des maladies cardiovasculaires et des lipides
Kapustnik et al. The use of herbal medicines with antiviral activity of plant origin for the treatment of diseases caused by COVID-19 infection

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20131129